Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature

摘要

Purpose Gender differences in patients diagnosed with non-functioning Pituitary Adenomas (NFPA) in a National Referral Center for Pituitary Tumors at the Federico II University of Naples, Italy. Methods Patients newly diagnosed with non-functioning sellar masses found on pituitary Magnetic Resonance Imaging from January 1st 2016 to December 31th 2018 underwent anthropometric measurements, basal evaluation of pituitary function, and metabolic assessment. Fatty live index (FLI) and visceral adiposity index (VAI) were calculated. Results Seventy-three patients (35 males, 51.1 ±17.0 years; 38 females, 41.8 ±18.1 years) presented with NFPA. Lesions >1 cm (85.7 vs. 47.3; χ~2=10.26,p = 0.001) and hypopituitarism (77.1 vs. 7.9; χ~2 = 33.29,p = 0.001) were more frequent in males than females. The highest sizes of pituitary adenomas were significantly associated with male gender (OR= 1.05, p = 0.049; R~2 = 0.060; IC 1.00-1.10). Headache (62.8 vs. 31.6; χ~2 = 5.96,p = 0.015) and visual field deficits (57.1 vs. 26.3; χ~2 = 5.93, p = 0.015) were significantly more frequent in males than in females. There was no sex difference in obesity prevalence, but the metabolic syndrome was more common among males than females (60.6 vs. 26.3; χ~2 = 7.14, p = 0.001). FLI was also higher in males (69.6 ±27.3 vs. 49.2 ±31.3; p< 0.001), while there were no differences in VAI. Conclusions Apart from the possible delay in the diagnosis induced by the gender differences in symptom presentation, the higher prevalence of macroadenomas amongst NFPA in males compared with females let to hypothesize a key role of the sex hormone profile as predictive factors of their biological behavior and metabolic profile. Further studies are, however, mandatory to better support the influence of gender differences on onset, progression, and metabolic consequences of NFPA.